ArticleClinical proteomics2026
ProteoBoostR: an interactive framework for supervised machine learning in clinical proteomics.
Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi-Omics and Machine Learning.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMass spectrometry-based proteomics enables high-throughput quantification of thousands of proteins in clinical samples, fueling biomarker discovery for disease diagnosis and prognosis. However, leveraging complex proteomic profiles for predictive modeling often requires advanced machine learning (ML) expertise that many biomedical researchers lack. User-friendly tools are needed to apply state-of-the-art ML algorithms to proteomics data. XGBoost is a powerful tree-based ML algorithm known for high accuracy in classification tasks, and has been successfully used to classify cancer subtypes from multi-omics data.
methodsWe developed ProteoBoostR, a Shiny application that streamlines supervised ML on protein abundance datasets. It allows researchers to train, evaluate and apply XGBoost classification models through an interactive web interface, without requiring coding.
resultsWe demonstrate the application of ProteoBoostR for the classification of proteomic subtypes across two independent datasets of glioblastoma multiforme, and for the detection of lung adenocarcinoma in serum. These application examples illustrate how ProteoBoostR can harness proteomic patterns for the stratification of patients.
conclusionsProteoBoostR is an open-source application that empowers proteomics researchers to perform advanced ML classification. It can be readily applied to other proteomic datasets and disease contexts, promoting reproducible ML analyses in proteomics and accelerating the translation of omics-based classifiers into clinical research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.